Scholarlink

<p>Osteoporosis and osteopenia are major public health concerns characterised by a progressive loss of bone mineral density (BMD) and an increased risk of fractures. Conventional diagnostic approaches primarily rely on BMD assessment, and it does not adequately reflect underlying molecular changes. Proteomics may help in identifying candidate biomarkers of bone loss. In this study, serum samples from <i>150 age-matched individuals</i> categorised as control, osteopenia, and osteoporosis based on dual-energy X-ray absorptiometry (DXA) T-score was analysed. Label-free quantitative (LFQ) proteomics was performed using <i>Orbitrap-based LC–MS/MS</i>. Pooled serum samples from each group underwent protein extraction, SDS-PAGE validation, and high-resolution mass spectrometric analysis. Differential protein expression was evaluated using fold change and log fold change (LogFC) metrics. A total of 2956 proteins were identified across all groups, indicating extensive proteomic coverage. Comparative analysis revealed significant dysregulation of proteins in osteopenia and osteoporosis, with more pronounced alterations in advanced disease. Key upregulated proteins included matrix metalloproteinase-21, pro-opiomelanocortin, and vasopressin receptor, while Ras-related C3 botulinum toxin substrate 3 (RAC3) and proteins involved in DNA repair and cellular regulation were markedly downregulated. Functional annotation demonstrated enrichment of pathways related to extracellular matrix remodelling, immune-inflammatory responses, hormonal signalling, and cytoskeletal organisation. Progressive proteomic changes from control to osteopenia and osteoporosis highlight early molecular shifts preceding severe bone loss. Orbitrap-based serum proteomics reveals systemic molecular alterations associated with declining BMD. These findings support the potential of proteomic signatures to improve early diagnosis, risk stratification, and therapeutic monitoring of osteoporosis. Further validation in larger cohorts is warranted to establish clinical applicability.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of novel diagnostic markers in progressive bone mineral density loss via serum proteomics analysis using orbitrap mass spectrometry

  • 期刊论文

  • 发表日期：

    2026年8月4日

查看全文
  • Chahat Sehgal,
  • Karanpreet Bhutani,
  • Isha Rani,
  • Rajendra Prasad

摘要

Osteoporosis and osteopenia are major public health concerns characterised by a progressive loss of bone mineral density (BMD) and an increased risk of fractures. Conventional diagnostic approaches primarily rely on BMD assessment, and it does not adequately reflect underlying molecular changes. Proteomics may help in identifying candidate biomarkers of bone loss. In this study, serum samples from 150 age-matched individuals categorised as control, osteopenia, and osteoporosis based on dual-energy X-ray absorptiometry (DXA) T-score was analysed. Label-free quantitative (LFQ) proteomics was performed using Orbitrap-based LC–MS/MS. Pooled serum samples from each group underwent protein extraction, SDS-PAGE validation, and high-resolution mass spectrometric analysis. Differential protein expression was evaluated using fold change and log fold change (LogFC) metrics. A total of 2956 proteins were identified across all groups, indicating extensive proteomic coverage. Comparative analysis revealed significant dysregulation of proteins in osteopenia and osteoporosis, with more pronounced alterations in advanced disease. Key upregulated proteins included matrix metalloproteinase-21, pro-opiomelanocortin, and vasopressin receptor, while Ras-related C3 botulinum toxin substrate 3 (RAC3) and proteins involved in DNA repair and cellular regulation were markedly downregulated. Functional annotation demonstrated enrichment of pathways related to extracellular matrix remodelling, immune-inflammatory responses, hormonal signalling, and cytoskeletal organisation. Progressive proteomic changes from control to osteopenia and osteoporosis highlight early molecular shifts preceding severe bone loss. Orbitrap-based serum proteomics reveals systemic molecular alterations associated with declining BMD. These findings support the potential of proteomic signatures to improve early diagnosis, risk stratification, and therapeutic monitoring of osteoporosis. Further validation in larger cohorts is warranted to establish clinical applicability.